All In Biotech

Drug Trial Radar · NCT05733598

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

A Phase 2, Open-label, Multicenter Study Investigating RP2 Oncolytic Immunotherapy in Combination With Second-line Therapy in Patients With Locally Advanced Unresectable, Recurrent and/or Metastatic Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 1, 2024

Primary completion

Dec 1, 2027

Study completion Jul 1, 2028

Sponsor

Lead sponsor
Replimune, Inc.Industry
Sponsor type
Industry
First posted
Feb 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced unresectable, recurrent, and/or metastatic HCC and in combination with durvalumab as treatment in patients with unresectable locally advanced or metastatic BTC.

Conditions

  • Hepatocellular Carcinoma
  • Biliary Tract Cancer

Interventions

  • RP2Biological

    Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.

  • BevacizumabBiological

    Anti-VEGF therapy.

  • AtezolizumabBiological

    Anti-PD-L1 monoclonal antibody.

  • DurvalumabBiological

    Anti-PD-L1 monoclonal antibody

  • RP2 MonotherapyBiological

    Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Response Rate per modified RECIST 1.1Time frame: From Day 1 up to 3 years after first RP2 dose of last patient.

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Beverly Hills Cancer Center

    Beverly Hills, California · Recruiting

  • UC San Diego Moores Cancer Center

    La Jolla, California · Recruiting

  • Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics)

    Miami, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • University of Maryland Medical Center

    Baltimore, Maryland · Recruiting

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York · Recruiting

  • Montefiore Medical CenterMontefiore Medical Park

    The Bronx, New York · Recruiting

  • University of Pennsylvania, Abramson Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • The West Clinic

    Germantown, Tennessee · Recruiting

  • University of Tennessee Medical Center

    Knoxville, Tennessee · Recruiting

  • Houston Methodist Hospital Cancer Center

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.